NEW YORK CITY -- Real-world operators have been leaving patients with acceptable but still less-than-optimal results after transcatheter mitral edge-to-edge repair (M-TEER), with some suggesting moving the goalposts for success.
The national Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) TVT Registry showed that the Pascal Precision M-TEER system in commercial experience was associated with 86.6% freedom from all-cause mortality or heart failure hospitalization (HFH) at 1 year in over 4,600 people with degenerative mitral regurgitation (MR).
While clinical event rates were low, and there were significant improvements in quality of life, at 1 year there were nevertheless just 68.4% of patients left with the ideal result of mild or less MR (≤1+) and 92.9% of the total group with moderate or less MR (≤2+), per site-reported data.
It turns out that 62.4% of Pascal M-TEER patients had achieved optimal hemodynamics -- MR ≤1+ and mitral valve gradients 5 mmHg or below -- by discharge in the first place, according to Azeem Latib, MD, of Montefiore Medical Center in New York City, presenting at the New York Valves annual meeting hosted by the Cardiovascular Research Foundation.
